Preview

Онкоурология

Расширенный поиск

НОВЫЕ МЕТОДЫ ПРОГНОЗА ЧУВСТВИТЕЛЬНОСТИ РАКА ПОЧКИ К ИММУНОТЕРАПИИ НА ОСНОВЕ АНАЛИЗА МОЛЕКУЛЯРНО-ГЕНЕТИЧЕСКИХ ХАРАКТЕРИСТИК ОПУХОЛИ

https://doi.org/10.17650/1726-9776-2010-6-3-57-62

Полный текст:

Аннотация

Приведен обзор литературы, посвещенный проблеме лечения рака почки, главным образом проведению послеоперационной иммунотерапии. Освещается роль цитокинов во взаимодействии опухоли и иммунной системы, определена прогностическая ценность величины экспрессии каждого цитокина в отношении как выживаемости пациента, так и эффективности иммунотерапии, а также использования этой информации для разработки новых терапевтических подходов.

Об авторах

М. Т. Айвазов
ФГУ РНЦРР, Москва
Россия


В. К. Боженко
ФГУ РНЦРР, Москва
Россия


А. Д. Каприн
ФГУ РНЦРР, Москва
Россия


Список литературы

1. Ferlay J., Autier P., Boniol M. et al. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 2007;18(3):581–92.

2. Jemal A., Siegel R., Ward E. et al. Cancer statitics, 2006. Cancer J Clin 2006;56(2):106–30.

3. Stafford H.S., Saltzstein S.L., Shimasaki S. et al. Racial/ethnic and gender disparities in renal cell carcinoma incidence and survival. J Urol 2008;179(5):1704–8.

4. Aron M., Nguyen M.M., Stein R.J., Gill I.S. Impact of gender in renal cell carcinoma: an analysis of the SEER database. Eur Urol 2008;54(1):133–40.

5. Лопаткин Н.А. Урология: национальное руководство. М.: ГЭОТАР-Медиа, 2009.

6. Аксель Е.М. Заболеваемость злокачественными новообразованиями мочевых и мужских половых органов в России в 2003 г. Онкоурология 2005; (1):6–9.

7. Robson C.J., Churchill B.M., Anderson W. The results of radical nephrectomy for renal cell carcinoma. J Urol 1969;101:297.

8. Lam J.S., Shvarts O., Pantuck A.J. Changing concepts in the surgical management of renal call carcinoma. Eur Urol 2004;45:692–705.

9. Sandock D.S., Seftel A.D., Resnick M.I. A new protocol for the follow-up of renal cell carcinoma based on pathological stage. J Urol 1995;154:28–31.

10. Levy D.A., Slaton J.W., Swanson D.A., Dinney C.P.N. Stage specific guidelines for surveillance after radical nephrectomy for local renal cell carcinoma. J Urol 1998;159:1163–7.

11. Eggener S., Reiher F.K., Campbell S.C. Surveillance for renal cell carcinoma after surgical management. Am Urol 2001;20:202–7.

12. Janzen N.K., Kim H.L., Figlin R.A. et al. Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. Urol Clin North Am 2003;30:843–52.

13. Stephenson A.J., Hakimi A., Snyder E. et al. Complications of radical and partial nephrectomy in a large contemporary cohort. J Urol 2004;171:130–4.

14. Theodorescu D., Rabbani F., Donat S.M. Follow up of genitourinary malignancies for the office urologist:A practical approach. Part 2: Kidney cancer and germ cell cancer of the testis . Am Urol 2004;23:310–5.

15. Uzzo R.G., Novick A.C. Nephron sparing surgery for renal tumors: Indications, techniques and outcomes. J Urol 2001;166:6–18.

16. Marshall F.F. Cryotherapy for small renal cell tumors: pro. Urology 1999;53:1077–8.

17. Murphy D.P., Gill I.S. Energy-based renal tumor ablation: A review. Semin Urol Oncol 2001;19:133–40.

18. Lowry P.S., Nakada S.Y. Renal cryotherapy: 2003 clinical status. Curr Opin Urol 2003;13:193–7.

19. Hinshaw J.L., Lee F.T. Imageguided ablation of renal cell carcinoma. Magn Reson Imaging Clin North Am 2004;12:429–47.

20. Mabjeesh N.J., Avidor Y., Haim M. Emerging nephron sparing treatments for kidney tumors: A continuum of modalities from energy ablation to laparoscopic partial nephrectomy. J Urol 2004;171:553–60.

21. Finke J.H., Rayman P., Hart L. et al. Characterization of tumor-infiltrating lymphocyte subsets from human renal cell carcinoma: Specific reactivity defined by cytotoxicity, interferon-gamma secretion and proliferation. J Immunol Emphasis Tumor Immunol 1994;15:91–104.

22. Tatsumi T., Kierstead L.S., Ranieri E. et al. Disease-associated bias in T helper type 1 (Th1)/Th2 CD4+ T cell responses against MAGE-6 in HLA-DRB10401+patients with renal cell carcinoma or melanoma. J Exp Med 2002;196:619–28.

23. Vestal D.J., Yi T., Borden C. Pharmacology of interferons: Induced proteins, cell activation and antitumor activity. In: Cancer chemotherapy and biotherapy. Chabner B.A., Longo D.L. eds. Philadelphia: Lippincott Williams & Wilkins, 2001; p. 752–78.

24. Alatrash G., Bukowski R.M., Tannenbaum C.S. et al. Interluken. In: Cancer chemotherapy and biotherapy – principles and practice. 4th ed. Chabner B.A., Longo D.L. eds. Philadelphia: Lippincott Williams & Wilkins, 2006. p. 767–808.

25. Coppin C., Porzsolt F., Awa A. et al. Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev 2005;CD001425.

26. Pyrhonen S., Salminen E., Ruutu M. et al. Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. J Clin Oncol 1999;17:2859–67.

27. Negrier S., Caty A., Lesimple T. et al; Groupe Français d'Immunothérapie, Federation Nationale des Centres de Lutte Contre le Cancer. Treatment of patients with metastatic renal carcinoma with a combination of subcutaneous interleukin-2 and interferon with or without fluorouracil. J Clin Oncol 2000;18:4009–15.

28. Motzer R.J., Murphy B., Bacik J. et al. Phase III trial of interferon alfa-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma. J Clin Oncol 2000;18:2972–80.

29. Fossa S.D., Mickisch G.H., De Mulder P.H.M. et al. Interferon-alfa with or without 13-cis retinoic acid in patients with progressive, measurable metastatic renal cell carcinoma. Cancer 2004;101:533–40.

30. Diaz-Montero C.M., Salem M.L., Nishimura M.I. et al. Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol Immunother 2009;58:49–59.

31. Ochoa A.C., Zea A.H., Hernandez C., Rodriguez P.C. Arginase, prostaglandins, and myeloid-derived suppressor cells in renal cell carcinoma. Clin Cancer Res 2007;13:721–6.

32. Griffiths R.W., Elkord E., Gilham D.E. et al. Frequency of regulatory T cells in renal cell carcinoma patients and investigation of correlation with survival. Cancer Immunol Immunother 2007;56:1743–53.

33. Lin E.Y., Nguyen A.V., Russell R.G., Pollard J.W. Colony-stimulating factor 1promotes progression of mammary tumors to malignancy. J Exp Med 2001;193:27–40.

34. Di Carlo E., Coletti A., Modesti A. et al. Local release of interleukin-10 by transfected mouse adenocarcinoma cells exhibits pro- and anti-inflammatory activity and results in a delayed tumor rejection. Eur Cytokine Netw 1998;9:61–8.

35. Polverini P.J., Leibovich S.J. Induction of neovascularization and nonlymphoid mesenchymal cell proliferation by macrophage cell lines. J Leukoc Biol 1985;37:279–88.

36. Huang S., Xie K., Bucana C.D. et al. Interleukin 10 suppresses tumor growth and metastasis of human melanoma cells:Potential inhibition of angiogenesis. Clin Cancer Res 1996;2:1969–79.

37. Jones D.H., Nakashima T., Sanchez O.H. et al. Regulation of cancer cell migration and bone metastasis by RANKL. Nature 2006;440:692–6.

38. Mikami S., Katsube K.-I., Oya M., Ishida M. Increased RANKL expression is related to tumour migration and metastasis of renal cell carcinomas. J Pathol 2009;218:530–9.

39. Casamassima A., Picciariello M., Quaranta M. et al. C-reactive protein: a biomarker of survival in patients with metastatic renal cell carcinoma treated with subcutaneous interleukin-2 based immunotherapy. J Urol 2005;173:52–5.

40. Masuda H., Kurita Y., Fukuta K. et al. Significant prognostic factors for 5-year survival after curative resection of renal cell carcinoma. Int J Urol 1998;5:418–22.

41. Zisman A., Pantuck A.J., Figlin R.A., Belldegrun A.S. Validation of the UCLA integrated staging system for patients with renal cell carcinoma. J Clin Oncol 2001;19:3792–3.

42. Fujikawa K., Matsui Y., Oka H. et al. Serum C-reactive protein level and the impact of cytoreductive surgery in patients with metastatic renal cell carcinoma. J Urol 1999;162:1934–7.

43. Karakiewicz P.I., Hutterer G.C., Trinh Q.D. et al. C-reactive protein is an informative predictor of renal cell carcinoma-specific mortality: a European study of 313 patients. Cancer 2007;110(6):1241–7.

44. Blay J.Y., Négrier S., Combaret V. et al. Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma. Cancer Res 1992;52:3317–22.

45. Stadler W.M., Richards J.M., Vogelzang N.J. Serum interleukin-6 levels in metastatic renal cell cancer: Correlation with survival but not an independent prognostic indicator. J Natl Cancer Inst 1992;84:1835–6.

46. Ljungberg B., Grankvist K., Rasmuson T. Serum interleukin-6 in relation to acute-phase reactants and survival in patients with renal cell carcinoma. Eur J Cancer 1997;33:1794–8.

47. Yoshida N., Ikemoto S., Narita K. et al. Interleukin-6, tumour necrosis factor alpha and interleukin-1beta in patients with renal cell cancer: Correlation with survival but not an independent prognostic indicator. J Natl Cancer Instr 1992;84:1835–6.

48. Miki S., Iwano M., Miki Y. et al. Interleukin-6 functions as an in vitro autocrine growth factor in renal cell carcinomas. FEBS Lett 1989;250:607–10.

49. Takenawa J., Kaneko Y., Fukumoto M. et al. Enhanced expression of interleukin-6 in primary human renal cell carcinomas. J Natl Cancer Instr 1991;83:1668–72.

50. Koo A.S., Armstrong C., Bochner B. et al. Interleukin-6 and renal cell cancer:Production, regulation, and growth effects. Cancer Immunol Immunother 1992;35:97–105.

51. Montrier-Caux C., Montmain G., Dieu M.C. et al. Inhibition of the differentiation of dendritic cells from CD34-progenitors by tumor cells: Role of interleukin-6 and macrophage colony-stimulating factor. Blood 1998;92:4778–91.

52. Dosquet C., Schaetz A., Faucher C. et al. Tumor necrosis factor- , interleukin-1β and interleukin-6 in patients with renal cell carcinoma. Eur J Cancer 1994;30:162–7.

53. Chuang M.J., Sun K.H., Tang S.J. et al. Tumor-derived tumor necrosis factor-alpha promotes progression and epithelial-mesenchymal transition in renal cell carcinoma cells. Cancer Sci 2008;99(5):905–13.

54. Sakaguchi S., Sakaguchi N., Asano M. et al. Immunologic selftolerance maintained by activated T cells expressing IL-2 receptor a-chains CD25. Breakdown of a single mechanism of selftolerance causes various autoimmune diseases. J Immunol 1995;155:1151–64.

55. Tang Q., Bluestone J.A.The Foxp3+regulatory T cell: a jack of all trades, master of regulation. Nat Immunol 2008;9(3):239–44.

56. O’Garra A., Vieira P. Regulatory T cells and mechanisms of immune system control. Nat Med 2004;10:801–5.

57. Fontenot J.D., Rudensky A.Y. A well adapted regulatory contrivance: regulatory T cell development and the forkhead family transcription factor Foxp3. Nat Immunol 2005;6:331–7.

58. Ziegler S.F. FOXP3: of mice and men. Ann Rev Immunol 2006;24:209–26.

59. Siddiqui S.A., Frigola X., Bonne-Annee S. et al. Tumor-infiltrating Foxp3-CD4+CD25+ T cells predict poor survival in renal cell carcinoma. Clin Cancer Res 2007;13(7):2075.

60. Cesana G.C., DeRaffele G., Cohen S. et al. Characterization of CD4+CD25+regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma. J Clin Oncol 2006;24:1169–77.

61. Webster W.S., Thompson R.H., Dong H. et al. Mononuclear ell infiltration in clear-cell renal cell carcinoma independently predicts patient survival. Cancer 2006;107:46–53.

62. Sozen S., Coskun U., Sancak B. et al. Serum levels of interleukin-18 and nitrite + nitrate in renal cell carcinoma patients with different tumor stage and grade. Neoplasma 2004;51(1):25–9.

63. Montero1 A.J., Diaz-Montero C.M., Millikan R.E. et al. Cytokines and angiogenic factors in patients with metastatic renal cell carcinoma treated with interferona: association of pretreatment serum levels with survival. Ann Oncol 2009;20:1682–7.

64. Matsuyama H., Yamamoto M., Yoshihiro S. et al. Efficacy of continuous subcutaneous infusion therapy using interferon alpha and the possible prognostic indicator of TNF-alpha in renal cell carcinoma. Int J Urol 1997;4(5):447–50.

65. Sonouchi K., Hamilton T.A.,Tannenbaum C.S. et al. Chemokine gene expression in the murine renal cell carcinoma, RENCA, following treatment in vivo with interferon-alpha and interleukin-2. Am J Pathol 1994;144:747–55.

66. Dosquet C., Schaetz A., Faucher C. et al. Tumor necrosis factor-α, interleukin-1β and interleukin-6 in patients with renal cell carcinoma.Eur J Cancer 1994;30:162–7.


Для цитирования:


Айвазов М.Т., Боженко В.К., Каприн А.Д. НОВЫЕ МЕТОДЫ ПРОГНОЗА ЧУВСТВИТЕЛЬНОСТИ РАКА ПОЧКИ К ИММУНОТЕРАПИИ НА ОСНОВЕ АНАЛИЗА МОЛЕКУЛЯРНО-ГЕНЕТИЧЕСКИХ ХАРАКТЕРИСТИК ОПУХОЛИ. Онкоурология. 2010;6(3):57-62. https://doi.org/10.17650/1726-9776-2010-6-3-57-62

For citation:


Aivazov M.T., Bozhenko V.K., Kaprin A.D. NEW METHODS FOR PREDICTING THE SENSITIVITY OF RENAL CANCER TO IMMUNOTHERAPY ON THE BASIS OF ANALYSIS OF MOLECULAR GENETIC CHARACTERISTICS OF A TUMOR. Cancer Urology. 2010;6(3):57-62. (In Russ.) https://doi.org/10.17650/1726-9776-2010-6-3-57-62

Просмотров: 183


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1726-9776 (Print)
ISSN 1996-1812 (Online)